Danny Brody

VP, The Green Organic Dutchman

Danny Brody is the Vice President of Investor Relations at The Green Organic Dutchman Holdings Ltd. (TGOD). Danny has more than ten years of experience in finance and holds a Chartered Investment Manager (CIM) designation from the Canadian Securities Institute (CSI).

Before leading TGOD to the most successful IPO in cannabis history, he was previously the Director of Investor Relations at Emblem Cannabis, and took the company public through a highly successful IPO.

Danny spent eight years in the brokerage industry, where he specialized in fundraising, building and maintaining client portfolios, financial advising, marketing, business development, structuring, advanced due diligence, lead generation, and database management before making the switch to the cannabis industry.

John Vardaman

Executive VP, Hypur Inc./ Co-Author, The Cole Memo

John Vardaman, III, is the Executive Vice President and General Counsel at Hypur Inc., which provides tech solutions for the banking and payments industries. John has 15 years of experience working as a senior government official on some of the most challenging issues facing the financial services industry. John was an Assistant Deputy Chief at the U.S. Department of Justice (DOJ), and served as Counsel to the Treasury Department. He played an instrumental role in devising the federal policy for enforcing the Bank Secrecy Act and anti-money laundering laws.

At the DOJ, he was actively involved in drafting the agency’s guidance regarding financial crimes related to state legalization of cannabis, and notably co-authored The Cole Memo. He was also instrumental in devising DOJ policy regarding the enforcement of laws governing the structuring of financial transactions.

Vardaman is a graduate of Vanderbilt University, and earned his law degree from Georgetown University.

Dr. Avtar Dhillon

Executive Chairman, Emerald Health Therapeutics/

Chairman, Cannabis Canada Association.

Dr. Avtar Dhillon is the Executive Chairman of Emerald Health Therapeutics, Inc. He also is the Chairman of the Advisory Board of Nemus Bioscience Inc. as well as its Executive Chairman.

Dr. Dhillon has more than 20 years of experience in building public companies through mergers and acquisitions, leading innovation in science, engineering and farming enterprises, securing government grants and NGO funding, and building intellectual property portfolios. Notably, he was an Executive Chairman at Inovio Pharmaceuticals, Inc. from 2009 to 2011, and CEO and President from 2001 to 2009.

Dr. Dhillon was elected first Board Chair of the Cannabis Canada Council, a national industry association for the cannabis sector. Dr. Dhillon holds a Bachelor of Science in Human Physiology and an M.D. from the University of British Columbia.

Jenn Larry

President of CBD Strategy Group

Jenn Larry is President of CBD Strategy Group. CBD Strategy is a communications, brand development, and design-focused firm built for the cannabis industry. Over the past 17 years, she’s worked across multiple sectors, including music, online gambling, pharmaceutical, tobacco, payments, technology, and consumer packaged goods.

Jenn previously worked as Vice President of Strategy and Operations for the Precision Communications Group. She was also the Strategic Planner – Digital Development at Ogilvy & Mather. These roles have allowed her to create and execute strategies and programs within emerging, disrupted, and regulated environments. She is well known for her ability to forecast trends, leverage business intelligence and lead change across organizations.

Dr. Michael Dor

Senior Medical Advisor, Israel Ministry of Health

Dr. Michael Dor is the Senior Medical Advisor at the Israeli Ministry of Health’s Medical Cannabis Unit. Dr. Dor has collaborated extensively with Israeli organic chemist Raphael Mechoulam, who is known as the “father of cannabis research” for his contributions to the field.

Dr. Dor has also served as the Head of the Hospitals Division and Deputy Director of the Health Management in the ministry, where he initiated the quality control and licensing process of the Hospitals and the Clinical services in Israel. He voluntarily started a clinic for uninsured refugees and a shelter for victims of human trafficking, for which he was awarded the Presidential Award in 2014 – the highest civilian honor in Israel.

After retiring from the Ministry, Dr. Dor took up his role with the Medical Cannabis Unit, where he’s introduced more indications and helped improve the process of approval for treatments. He’s also continued his work as a family physician, and teaches at Ariel University and Hadassah College as a senior lecturer. Dr. Dor graduated from Tel Aviv University and earned a Master’s degree from Harvard University’s Kennedy School of Government. He continues to work as a practicing physician.

Michael A. Robinson

Director of Venture Capital and Technology Research, Money Morning

Michael A. Robinson is a 35-year Silicon Valley veteran and one of the top technology financial analysts working today. Michael is a consultant, senior adviser, and board member for Silicon Valley venture capital firms. He was one of five people involved in early meetings for the $160 billion “cloud” computing phenomenon, and was with Dave DeWalt, CEO of McAfee, right before Intel acquired his company for $7.8 billion.

Michael is a regular guest and panelist on CNBC and Fox Business. He’s also a Pulitzer Prize-nominated writer and reporter. Michael is a contributor to Money Morning and writers regularly about cannabis industry investing in Strategic Tech Investor, the Nova-X Report and Radical Technology Profits publications. He’s also worked for The New York Times and The Wall Street Journal.

Ernie Tremblay 

Biotech Investing Specialist, Money Morning

Ernie Tremblay has more than 25 years of experience in following and analyzing the latest developments in health, medicine, and related technologies. As a health editor and writer, Ernie has contributed to more than 100 publications on topics like diabetes, Alzheimer’s disease, arthritis, dermatology, and groundbreaking medical therapies for publishers like Prentice Hall, Harper Collins, and others. Through the years, he’s gained “insider” access to some of the world’s top medical professionals, including Nobel-caliber doctors the Yale School of Medicine’s Dr. Karel Liem, Jr., and Harvard Medical School’s Dr. William S. Beck.

Ernie contributes to Money Morning, and writes about biotech investing in his Biotech Insider Alert. He has a thorough understanding of the Food and Drug Administration (FDA) approval process, as well as the “hard science” behind new, experimental drugs and the market demand for them.